Ascentage Pharma Group International vs Amphastar Pharmaceuticals
AAPG and AMPH side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AAPG and AMPH compare
Amphastar Pharmaceuticals grew revenue faster over the last twelve months (3.1% versus −41.5% for Ascentage Pharma Group International).
Amphastar Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 13.3% compared with −216% at Ascentage Pharma Group International.
Amphastar Pharmaceuticals scores higher on the StockData Score (13 against 3 for Ascentage Pharma Group International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AAPG | AMPH |
|---|---|---|
| Size and price | ||
| Market cap | – | $1.2B |
| Share price | $15.00 | $28.60 |
| Change, 1 year | −53.7% | 9.5% |
| Change, 5 years | – | 39.4% |
| Beta (5Y) | 0.81 | 0.57 |
| Employees | 767 | 163 |
| StockData Score | ||
| Total score | 3 | 13 (better) |
| Valuation score | 0 | 6 (better) |
| Growth score | 1 | 1 |
| Performance score | 1 | 3 (better) |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 13.0× |
| P/S | – | 1.6× |
| P/B | – | 1.5× |
| EV/EBITDA | – | 11.4× |
| P/FCF | – | 8.8× |
| PEG | – | 2.47 |
| FCF yield | – | 11.4% |
| Fair value | – | $42.53 |
| Margin of safety | – | 32.7% |
| Growth | ||
| Revenue growth (TTM) | −41.5% | 3.1% (better) |
| Revenue growth, 5Y average | – | 15.5% |
| Net income growth (TTM) | – | −11.3% |
| EPS growth (TTM) | – | −2.7% |
| EPS growth, 5Y average | – | 132% |
| Profitability | ||
| Gross margin | 91.5% (better) | 46.8% |
| Operating margin | – | 18.7% |
| Net margin | −216% | 13.3% (better) |
| FCF margin | −209% | 18.6% (better) |
| Return on equity | −156% | 12.4% (better) |
| Return on invested capital | – | 9.3% |
| Financial health | ||
| Debt / equity | 1.50 | 0.75 (better) |
| Net debt / EBITDA | – | 2.74 |
| Interest coverage | – | 5.3× |
| Current ratio | 1.79 | 3.32 (better) |
| Altman Z-score | – | 2.42 |
| Piotroski F-score | – | 6 |
| Dividends and buybacks | ||
| Buyback yield | – | 7.9% |
| Shareholder yield | – | 7.9% |
| Ownership | ||
| Held by institutions | 0.00% | 66.6% |
| Held by insiders | 13.0% | 38.7% |
| Insider net buying, 12 months | – | −$1.9M |
| Short interest, % of float | – | 16.3% |
Go deeper
- AAPG stock overview
- AAPG income statement
- AAPG valuation and score
- AMPH stock overview
- AMPH income statement
- AMPH valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.